Prefer to view this content on our website? Click here.
Dear Fellow Investor,
Insiders Are Aggressively Buying These Down, But Not Out, Stocks
When it comes to investing, few signals are as powerful as insider buying. After all, who knows a company better than the people running it?
CEOs, CFOs, and board members spend every day immersed in the numbers, strategies, and future outlook of their companies. When they open their wallets to buy shares of their own stock on the open market, it often signals one thing: confidence. Unlike stock buybacks authorized by the board, insider purchases are personal. Executives are risking their own capital, often in the face of short-term uncertainty, because they believe the long-term payoff could be significant.
For individual investors, tracking insider activity can be one of the best ways to spot potential opportunities—especially in beaten-down stocks that may be due for a rebound. Insiders don’t always get it right, but history has shown that heavy insider buying often precedes recoveries.
Recently, two companies have seen aggressive insider buying despite short-term volatility. Let’s take a closer look.
Guy Stocks
Don’t Miss Tomorrow’s Market-Moving Opportunity
Something big is dropping tomorrow morning at 8:00 AM, and we want to make sure you’re on the inside track.
Guy Stocks is releasing a brand-new alert on a company operating in one of the fastest-growing and most exciting sectors of the market today.
This is the kind of opportunity that savvy investors watch closely — and having early access could be key.
Our alerts are designed to put you ahead of the curve, providing timely insights before the broader market even notices.
Tomorrow’s alert will highlight a company with enormous potential, multiple upcoming catalysts, and a story that could reshape its space.
👉Click here to sign up now for Guy Stocks alerts today so you’re ready to see this report the moment it goes live. Don’t wait — once the alert drops, you’ll want to be first in line.
(By clicking the link above, you agree to receive emails from GuyStocks.com. You can opt out at any time.)
Company: Dollar Tree (SYM: DLTR)
Shares of Dollar Tree have been under pressure in recent weeks. After rallying earlier this year, the stock tumbled from around $115 to below $95 following its latest earnings report.
The company did manage to beat Wall Street’s expectations for the quarter, but investors focused on its soft guidance for Q3 adjusted earnings. That weaker outlook sparked selling pressure, pushing DLTR to multi-month lows.
But not everyone is running for the exits. In fact, insiders are stepping up.
-
CFO Stewart Glendinning purchased 500 shares at $99.50 shortly after the dip.
-
A few days later, he bought another 3,000 shares at prices between $97.00 and $97.87.
For a top executive to commit this kind of capital so close to earnings suggests conviction that the stock’s current weakness is temporary.
Wall Street is also taking notice. Morgan Stanley recently raised its price target on DLTR to $105, up from $96. Analysts at the firm noted that Dollar Tree’s top-line trends remain solid and could continue into the second half of 2025, indicating confidence in the company’s revenue performance.
Why Dollar Tree Could Bounce Back
-
Resilient business model – Dollar Tree thrives in uncertain economic times. As inflation and consumer pressures persist, shoppers continue to flock to discount retailers.
-
Proven growth drivers – The company’s Family Dollar integration and store renovation initiatives are aimed at boosting same-store sales and improving margins.
-
Attractive valuation – After the recent selloff, DLTR is trading well below its 52-week high, offering investors a potential value entry point.
With insiders showing conviction and analysts turning more bullish, Dollar Tree looks like a stock worth watching closely.
When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to President Trump. But many viewers missed an even more important moment in that 30-second clip. One that unmistakably singled out what Futurist Eric Fry calls "possibly the best AI investment anyone could make right now." Eric believes this little-known partner to Apple could go crazy over the next 12-24 months, potentially leaving well-known AI stocks like Nvidia, Microsoft and Google in the dust.
Company: Cassava Sciences (SYM: SAVA)
If Dollar Tree represents a beaten-down retail recovery play, Cassava Sciences is the classic high-risk, high-reward biotech story.
The stock collapsed late last year after the company announced it would stop clinical studies of its Alzheimer’s drug, simufilam. With sentiment crushed, shares plummeted into penny-stock territory, trading near $2 per share.
But just recently, a massive insider purchase has turned heads.
-
President and CEO Remi Barbier bought 237,941 shares for roughly $534,743.
-
The shares were purchased between September 18–19, at prices ranging from $2.13 to $2.29.
Such a large, open-market purchase from the company’s top executive signals strong belief in the company’s pipeline and future direction.
Why Insiders Are Buying
Cassava is pivoting its focus to a new program targeting TSC-related epilepsy (tuberous sclerosis complex), a rare disease with limited treatment options. According to the company, two encouraging animal model studies—one at Yale and another with the TSC Alliance—support simufilam’s potential as a novel therapy.
Management recently announced that, following positive preclinical data, it plans to advance simufilam into a clinical study in 1H 2026.
While Alzheimer’s remains an incredibly challenging therapeutic area, this new direction may offer fresh opportunities for the company to deliver value.
Why SAVA Could See Upside
-
Massive insider confidence – Few things scream confidence like a CEO buying nearly a quarter-million shares after a brutal decline.
-
Rare disease focus – Targeting niche conditions like TSC-related epilepsy can sometimes fast-track approvals and generate strong pricing power.
-
Speculative upside – At such depressed valuations, even modest clinical progress could send the stock sharply higher.
Of course, biotech investing comes with substantial risk. Drug development timelines are long, regulatory hurdles are high, and trial results are unpredictable. Still, for risk-tolerant investors, following insider buying at beaten-down levels can sometimes lead to outsized returns.
Trade Algo
Is this your new #1 enemy in trading?
Imagine this scenario…You are a super-intelligent investor who can scan through millions of data, detect patterns, and execute savvy trades… in just minutes.
It would be an unfair advantage, right?
Welcome to the AI Age, where AI can make trading decisions in milliseconds.
Take Minotaur Capital as an example.
The hedge fund replaced human analysts with AI… and… ended up beating the benchmark index by more than two times.
Here's the good news...
You can get a taste of using A.I. technology to find the top momentum trades.
As a Behind the Markets reader, we’d like to offer you a SPECIAL gift where you can sign up for our SMS “dark pool alerts” for FREE.
Click here to claim FREE SMS dark pool alerts now.
Are there any other stocks with recent insider buying that you've got your eye on? What other sectors of the market do you think are on their way up right now? Hit "reply" to this email and let us know your thoughts!
0 التعليقات:
إرسال تعليق